Cost‑of‑illness studies in nine Central and Eastern European countries by Brodszky, Valentin et al.
Vol.:(0123456789) 
The European Journal of Health Economics (2019) 20 (Suppl 1):S155–S172 
https://doi.org/10.1007/s10198-019-01066-x
ORIGINAL PAPER
Cost‑of‑illness studies in nine Central and Eastern European countries
Valentin Brodszky1  · Zsuzsanna Beretzky1,9 · Petra Baji1  · Fanni Rencz1,2  · Márta Péntek1  · Alexandru Rotar3  · 
Konstantin Tachkov4  · Susanne Mayer5  · Judit Simon5,10  · Maciej Niewada6  · Rok Hren7,8 · László Gulácsi1 
Received: 30 March 2019 / Accepted: 15 April 2019 / Published online: 18 May 2019 
© The Author(s) 2019
Abstract
Background To date, a multi-country review evaluating the cost-of-illness (COI) studies from the Central and Eastern 
European (CEE) region has not yet been published. Our main objective was to provide a general description about published 
COI studies from CEE.
Methods A systematic search was performed between 1 January 2006 and 1 June 2017 in Medline, EMBASE, The Cochrane 
Library, CINAHL, and Web of Science to identify all relevant COI studies from nine CEE countries. COI studies reporting 
costs without any restrictions by age, co-morbidities, or treatment were included. Methodology, publication standards, and 
cost results were analysed.
Results We identified 58 studies providing 83 country-specific COI results: Austria (n = 9), Bulgaria (n = 16), Croatia (n = 3), 
the Czech Republic (n = 10), Hungary (n = 24), Poland (n = 11), Romania (n = 3), Slovakia (n = 3), and Slovenia (n = 4). 
Endocrine, nutritional, and metabolic diseases (18%), neoplasms (12%), infections (11%), and neurological disorders (11%) 
were the most frequently studied clinical areas, and multiple sclerosis was the most commonly studied disease. Overall, 57 
(98%) of the studies explicitly stated the source of resource use data, 45 (78%) the study perspective, 34 (64%) the costing 
method, and 24 (58%) reported at least one unit costs. Regardless of methodological differences, a positive relationship was 
observed between costs of diseases and countries’ per capita GDP.
Conclusions Cost-of-illness studies varied considerably in terms of methodology, publication practice, and clinical areas. 
Due to these heterogeneities, transferability of the COI results is limited across Central and Eastern European countries.
Keywords Cost-of-illness · Disease burden · Central and Eastern Europe · Austria · Bulgaria · The Czech Republic · 
Croatia · Hungary · Poland · Romania · Slovakia · Slovenia
JEL Classification I10
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1019 8-019-01066 -x) contains 
supplementary material, which is available to authorized users.
 * Valentin Brodszky 
 valentin.brodszky@uni-corvinus.hu
1 Department of Health Economics, Corvinus University 
of Budapest, Fővám tér 8., 1093 Budapest, Hungary
2 Hungarian Academy of Sciences, Premium Postdoctoral 
Research Program, Nádor u. 7, 1051 Budapest, Hungary
3 Department of Social Medicine, University of Amsterdam, 
Meibergdreef 9, 22660, 1100 DD Amsterdam, 
The Netherlands
4 Department of Social Pharmacy and Pharmacoeconomics, 
Faculty of Pharmacy, Medical University of Sofia, 2, Dunav 
str., 1000 Sofia, Bulgaria
5 Department of Health Economics, Center for Public Health, 
Medical University of Vienna, Kinderspitalgasse 15/1, 
Vienna 1090, Austria
6 Department of Experimental and Clinical Pharmacology, 
Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, 
Poland
7 Institute of Mathematics, Physics, and Mechanics, Jadranska 
19, 1000 Ljubljana, Slovenia
8 Department of Physics, University of Ljubljana, Jadranska 
19, 1000 Ljubljana, Slovenia
9 Doctoral School of Business and Management, Corvinus 
University of Budapest, Fővám tér 8., 1093 Budapest, Hungary
10 Ludwig Boltzmann Institute Applied Diagnostics, Währinger 
Gürtel 18-20, Vienna 1090, Austria
S156 V. Brodszky et al.
1 3
Introduction
Cost-of-illness (COI) studies provide information on the 
economic burden of a specific disease from a societal, pub-
lic payer, family or individual perspective. They aim to 
evaluate not only the disease-related healthcare costs but 
also the overall costs to society, including both medical and 
non-medical costs. COI studies can aid the understanding of 
the importance of a health problem, estimate the main cost 
components and the cost structure, and, thus, provide valu-
able cost estimates for use in full economic evaluations [1]. 
As a result, COI studies are an important type of health eco-
nomic analysis aiming to support health policy and financ-
ing decision-making processes [2]. Over the past decade, 
health technology assessment has been implemented in most 
Central and Eastern European (CEE) countries, which, in 
turn, necessitates reliable, local country-specific COI stud-
ies [3–5].
There are no gold standard methods for calculating COI 
estimates [6–8]. Although standardization of the methods 
used in COI studies is becoming more and more impor-
tant to allow comparability, studies apply different designs, 
methodologies, perspectives, and costing approaches [9, 10]. 
Until now, several systematic reviews of COI studies have 
been conducted; however, most of them were focusing on 
one specific disease. Few reviews targeted a single specific 
cost item or component, such as informal care, direct medi-
cal costs, productivity loss, a specific geographic area, or a 
specific methodological aspect [10–13]. Nonetheless, COI 
studies from CEE countries have not been reviewed to date, 
with the exception of Austria [13].
This review has been undertaken to provide a description 
of the COI studies in nine CEE countries, namely Austria, 
Bulgaria, the Czech Republic, Croatia, Hungary, Poland, 
Romania, Slovakia, and Slovenia, in the past 10 years. The 
main objectives were to describe study characteristics, meth-
odology, and the COI estimates reported. First, we provide 
an overview of applied methods. Then, we present and com-
pare the COI estimates across CE countries.
Methods
Search strategy
We conducted a systematic review following the PRISMA 
statement [14]. A literature search was performed using 
Medline, EMBASE, The Cochrane Library, CINAHL, and 
Web of Science databases to identify studies that report data 
on the cost of a disease. The search strategy was based on 
the keyword “cost of illness” and the name of the given 
CEE country (online Appendix 1). The search was limited to 
studies published in the past 10 years (1 January 2006—31 
October 2016) and was updated on 30 June 2017 to shorten 
the time between the end of the search period and publica-
tion date. No language restrictions were applied. A com-
plementary, non-systematic literature search was conducted 
in three countries. Three authors (SM, KT, and ZB) hand-
searched for further papers in selected, peer-reviewed, non-
indexed local journals in Austria, Bulgaria, and Hungary. 
The review protocol was not registered.
Study selection
After removing duplicates, titles and abstracts of stud-
ies were reviewed independently by ZB, VB, and LG, and 
were retrieved if at least one of the reviewers considered the 
study to be relevant. First, abstracts (publication type) and 
reviews (publication type) were excluded. Full-text papers of 
the remaining studies were reviewed and included (ZB, VB, 
and LG). Any disagreement between reviewers was solved 
by discussions among the authors to reach consensus.
Studies were selected for further analysis if they met the 
following inclusion criteria: (i) COI data included for a spe-
cific disease without major restriction on the patient popula-
tion, e.g., by age, co-morbidity, complication, or treatment, 
(ii) full-text paper, (iii) original research, and (iv) the study 
population was recruited in Austria, Bulgaria, the Czech 
Republic, Croatia, Hungary, Poland, Romania, Slovakia, or 
Slovenia. Studies were not selected for further analysis if 
they represented clinical trials, reviews, cost-effectiveness 
studies, budget impact analyses, treatment-related (drug) 
studies, costs of health programs (e.g., screening), or stud-
ies enrolling a patient population with co-morbidities (e.g., 
diabetic patient with depression).
Data extraction
A Microsoft Excel spreadsheet was developed to extract data 
from the identified studies, including general characteris-
tics of the study (year of publication, geographical location, 
language, and funding source), methodological details of 
the study (disease, data collection method, study design, 
setting, costing year, currency, and perspective and costing 
methods), and results (direct costs, indirect costs, and total 
costs in euros). The list of extracted variables was created 
based on health economic checklists and adjusted by screen-
ing of six (10%) random articles [6, 15]. Costs reported in 
currencies other than euro were converted to euro at a mean 
annual exchange rate, and all costs were inflated to 2017 
prices using the harmonised consumer price index extracted 
from Eurostat [16]. To facilitate cross-country comparisons, 
costs were also described as a percentage of 2017 GDP per 
capita. Diseases were categorised according to the Inter-
national Statistical Classification of Diseases and Related 
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Health Problems 10th Revision (ICD-10 Version:16) [17]. 
Data extraction was conducted by ZB and respective authors 
for national languages and double-checked.
Results
Study selection
As can be seen from Fig. S1 (online Appendix), after remov-
ing 246 duplicates, the search in the electronic databases 
resulted in 607 potentially relevant papers. Of these studies, 
55 were not full-text papers and 98 were reviews. Further-
more, 282 papers did not report disease-related costs, 54 
focused on costs of multiple diseases, and 67 focused on 
the cost of a certain treatment. Overall, 50 articles from the 
electronic search fulfilled the inclusion criteria. The sup-
plementary local search resulted in another eight relevant 
articles in non-indexed, peer-reviewed journals (Austria: 
n = 2, Bulgaria: n = 5, and Hungary: n = 1).
Altogether, we included 58 articles (involving also multi-
country studies) that reported results for Hungary (n = 24), 
Bulgaria (n = 16), Poland (n = 11), Czech Republic (n = 10), 
Austria (n = 9), Slovenia (n = 4), Croatia (n = 3), Slovakia 
(n = 3), and Romania (n = 3).
Thirteen additional COI studies did not meet to our eli-
gibility criteria (e.g., involved samples restricted by age, 
co-morbidity, complication, or treatment), but we found 
their results worthy of attention, and hence, a summary of 
their characteristics and main results is presented in online 
Appendix 1.
Study characteristics
The majority of publications reported costs from one coun-
try (74%), but 15 studies presented results from multiple 
countries, and hence, altogether, 83 country-specific results 
were provided by 58 studies (Table 1). Three-quarters of the 
studies were published in English (n = 44), and except for 
five papers [18–22], all non-English papers had an English 
abstract. Most of the publications (n = 45, 78%) presented 
costs in euro. In 37 studies, the national currency was con-
verted to euro; of them, 17 (46%) studies stated explicitly 
exchange rate, 5 (14%) studies reported only the source of 
exchange rate, and 15 (40%) studies did not mention conver-
sion at all. Among countries outside the euro zone, reporting 
costs in national currency was most common in Romania 
(67%). Overall, 47 (81%) studies stated the source of fund-
ing. The lack of a funding statement was most prevalent in 
Romania (n = 2, 67%) and in Bulgaria (n = 5; 31%). Only two 
studies received funds from two different sources, both of 
them were funded by the European Union (EU) and the local 
government. Regarding clinical areas, endocrine, nutritional, 
and metabolic diseases were the most common, in which 
costs were analysed (n = 15 country-specific results), fol-
lowed by neoplasms (n = 12), and certain infectious and 
parasitic diseases (n = 10) (Fig. 1). Altogether 48 different 
diseases were analysed in the 58 included articles.
Methods
Analyses by countries are presented in Table 1. The most 
frequently used data source was a retrospective, self-com-
pleted resource use questionnaire (48%), followed by retro-
spective claims data analysis (14%) and prospective diary 
(14%). Sample sizes ranged from n = 2 (small cohorts) to 
n = 127,512 (large population-based study). Of the 58 stud-
ies included in the review, 26 (45%) presented aggregated 
results for each main cost category (i.e., direct medical, 
direct non-medical, and indirect). The majority of studies 
applied the societal perspective (52%), followed by the pub-
lic payer perspective (17%). If reported, bottom–up (38%) 
and top–down (21%) methods were used for estimating the 
costs in the studies. Productivity losses were estimated in 
47 (81%) studies; of them, the human capital approach and 
friction cost method were used in 34 (72%) and 11 (23%) 
studies, respectively, and the method was not specified in 
11 (23%) studies. Studies that reported costs of informal 
care (n = 29) applied the proxy-good method (17%) or the 
opportunity cost method (10%), but the name of the applied 
method was not stated in most of them (69%). Unit costs 
were not reported at all in 58% of the studies.
Cost‑of‑illness: comparison across countries in one 
disease
Eighty-three COI estimates were reported for 48 differ-
ent diseases. Apart from rare diseases, multiple sclerosis 
caused the highest economic burden in terms of average total 
annual cost per patient in three countries (Austria €50,599, 
the Czech Republic €14,777, and Poland €12,343) [23–25]. 
In Hungary, schizophrenia (€15,187), and in Bulgaria, ges-
tational diabetes (€32,263) were the most costly diseases 
[22, 26].
Multi-country studies were conducted in nine diagnoses 
(rotavirus gastroenteritis, pneumonia, bladder cancer, hypo-
glycaemia, Duchenne muscular dystrophy, epidermolysis 
bullosa, Prader–Willi syndrome, cystic fibrosis, and hae-
mophilia). One multi-country study (bladder cancer) was 
conducted in nine countries and another (hypoglycaemia) 
in six countries. Two studies were conducted (rotavirus 
gastroenteritis and pneumonia) in four countries and four 
studies (Duchenne muscular dystrophy, epidermolysis bul-
losa, Prader–Willi, and haemophilia) in two countries. The 
bladder cancer study involving nine countries resulted in 
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mean total costs of €7421; however, costs differed signifi-
cantly among countries, as the total cost was between €2320 
(Bulgaria) and €16,479 (Slovenia). The direct medical cost 
ranged between €1090 (Bulgaria) and €8050 (Slovenia), 
and indirect cost varied between €912 (Bulgaria) and €6398 
(Slovenia). The hypoglycaemia study was conducted in six 
countries, and the total overall societal cost per patient with 
diabetes was €11 and ranged between €5 (Bulgaria) and 
€18 (Slovenia) [27]. Rotavirus gastroenteritis and pneu-
monia studies were conducted in four countries and the 
average total costs were €541 and €764, respectively. Costs 
varied between €494 (Czech Republic) and €747 (Poland) 
in rotavirus gastroenteritis, and between €472 and €1111 
in pneumonia. Duchenne muscular dystrophy, epidermoly-
sis bullosa, Prader–Willi syndrome, cystic fibrosis, and 
haemophilia were studied in two countries (Hungary and 
Bulgaria) applying the same methodology in a European 
Commission founded rare disease study (BURQOL-RD pro-
ject). Prader–Willi syndrome was the least costly (Bulgaria: 
€3842 Hungary: €12,532) and mucopolysaccharidosis was 
the most costly rare disease (Bulgaria: €77,414; Hungary: 
€25,326) [28, 29].
Fig. 1  Distribution of COI studies by ICD classification. a Distribution of country-specific results across clinical areas defined by ICD groups 
(n = 83). b Distribution of studies between clinical areas defined by ICD groups (n = 58)
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Unique studies in more than one country were conducted 
in eight diagnoses, namely multiple sclerosis, dementia, Par-
kinson’s disease, rheumatoid arthritis, osteoporosis, chronic 
obstructive pulmonary disease (COPD), systemic sclerosis, 
and diabetes. Multiple sclerosis and diabetes were studied 
most often (four studies each), while three unique studies 
in three different countries were conducted in Parkinson’s 
disease and two unique studies in three different countries 
were conducted in cystic fibrosis. Two unique studies on 
both dementia and COPD were conducted in two different 
countries. In multiple sclerosis, there was a 4.1 times dif-
ference in total costs between Austria (€50,599) and Poland 
(€12,343) [24, 30]. In diabetes, the highest direct cost was 
observed in Hungary (€1309) and the lowest total cost was 
observed in Bulgaria (€472) [31, 32]. In Parkinson’s dis-
ease, there was a 3.3 times difference in total costs between 
Austria (€22,984) and the Czech Republic (€6970) [33, 34]. 
In dementia, we found a 3.5 times difference in total costs 
between the Czech Republic (€2013) and Hungary (€671) 
[35, 36]. The costs of COPD were similar in Bulgaria 
(€1839) and Romania (€2103) [21, 37].
Adjusting costs for GDP per capita level, differences 
between countries decreased (Table 2). For instance, a 7.1-
fold difference in bladder cancer and a 4.1-fold difference in 
multiple sclerosis were reduced to 2.4- and 1.5-fold, respec-
tively. Comparing diseases with available cost estimates 
from more than one country (Fig. 2), a positive relationship 
was identified between costs and GDP per capita. 
Discussion
A systematic search was conducted to provide a review of 
the COI studies in nine CEE countries. The diffusion of 
the new technologies to the health scare systems is enor-
mous, prices, and technologies, and professional guidelines 
are changing; therefore, our search was limited for the past 
10 years. The included papers covered a broad range of clini-
cal areas and showed notable cross-country differences in 
terms of methodology and publication standards as well as 
the average yearly costs per patient.
Study characteristics and methodology
Reporting cost results in euros was dominant over national 
currencies, suggesting that researchers in the CEE region 
find it important to make their results available for the 
international scientific community and allow for com-
parability with other studies. To assess study quality, we 
selected some quality indicators, such as those are used in 
health economics checklists. Reporting study perspective, 
reference year, costing method (top–down vs. bottom–up), 
source of resource use, valuation of informal care, valuation 
of productivity loss, and funding source were considered 
as quality indicators. We find it noteworthy to mention that 
whilst the source of data on resource utilization and refer-
ence year of costing were stated in nearly every paper (98% 
and 95%, respectively), other important quality indicators 
were less often reported. The study perspective was reported 
in 78%, the approach to valuing indirect costs in 77%, cost-
ing method in 64%, at least one unit cost in 42%, and method 
for valuing informal care in 31% of the studies. A recent 
review of economic evaluations in Austria found that the 
study perspective and reference year were not reported by 
60% and 25% of the studies, respectively [13]. Differences 
may be explained by inclusion of non-peer-reviewed or grey 
literature (e.g., economic evaluation reports from national 
health technology assessment agencies) and of other forms 
of economic evaluations in the study by Mayer et al. The 
review by Mayer et al. included 93 (partial and full) eco-
nomic evaluations, 14 of which were cost-of-illness analy-
ses. Out of the 93 included studies, 23 were not indexed 
according to the Journal Citation Reports (Social) Sciences 
Edition and 12 were non-peer-reviewed reports [13].
Clinical areas
A large variety of diseases was covered by the studies, and 
most of them occurred in a one study. Each disease was stud-
ied by, on average, 1.3 papers. Considering country-specific 
results by ICD categories, endocrine, nutritional, and meta-
bolic diseases (18%), neoplasms (14%), infectious (12%), 
neurologic (11%), and musculoskeletal diseases (11%) 
represented the five main fields of COI research in CEE. 
It is difficult to judge the drivers of the selection of clinical 
fields. The public health importance of a disease might be an 
important factor as, for instance, all the studies in the ‘Endo-
crine, nutritional and metabolic diseases’ ICD category were 
related to diabetes, and among neoplasms studies, the most 
prevalent malignancies (breast, colorectal, lung, and pros-
tate cancer) were present (Table 2). According to the Global 
Burden of Disease study, the leading three causes of total 
Disability-Adjusted Life Years (DALY) included ischaemic 
heart disease, cerebrovascular disease, and lower respira-
tory infection, comprising 16% of all DALYs [38]. Leading 
causes of DALYs were represented only in six (10%) stud-
ies (cerebrovascular disease: n = 1, ischaemic heart disease: 
n = 2, and lower respiratory infection: n = 3) in our review, 
questioning public health importance as a driver of topic 
selection in COI studies. The need for COI data to support 
decision-making on reimbursement of highly effective but 
costly new drugs seems to be another relevant issue, and this 
hypothesis is supported by the relatively high rate of studies 
in inflammatory rheumatic diseases, where biological drugs 
were introduced in the CEE countries in the observed period. 
Multiple sclerosis is another disorder where biologicals 
S162 V. Brodszky et al.
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revolutionized the treatment that partly explains the rela-
tively high rate of neurological studies in the region. Moreo-
ver, when counting papers, neurologic diseases were most 
frequently studied (19%). A possible explanation could be 
that neurologic conditions in the CEE region were priorities 
for state-funded or EU-funded research. Eight out of the ten 
COI studies focusing on neurologic diseases received fund-
ing from the local governments or EU organisations. It is 
interesting that neurologic diseases were found also the most 
frequently studied clinical area according to a recently pub-
lished systematic review of EQ-5D studies in the CEE region 
[39]. These results suggest that neurologic diseases have a 
high priority in health economics research in the CEE.
Comparison of costs across countries
With respect to diseases for which cost estimates were pre-
sent in multiple countries, costs varied substantially across 
countries. However, there are apparent differences in the 
level of comparability between studies. There were multi-
country studies following a standardized methodology in 
which more than one CEE country together with Western 
European countries was participated. We also identified 
single-country studies in various diseases using very differ-
ent methods. Both multi-country and single-country stud-
ies reported significant cost differences in diseases across 
countries.
For the interpretation of data, it is important to take into 
consideration that the number of patients, sample character-
istics (e.g., age, gender, disease duration, and disease sever-
ity), and the availability of costly treatments at the time of 
the study (e.g., biological drugs for inflammatory diseases) 
varied a great deal across studies that may strongly influence 
the COI results and their comparability. Large differences 
in unit costs can also cause significant variations in costs. 
In bladder cancer, for example, the cost of an inpatient day 
was seven times higher in Austria (€495) than in Romania 
(€67). Methodological differences, such as prevalence- and 
incidence-based costing, form an obstacle for the compari-
son of costs. Therefore, the incidence-based prostate cancer 
study by Brodszky et al. cannot be compared with the prev-
alence-based prostate cancer study by Inotai et al., although 
both studies were conducted in Hungary [40, 41]. It should 
also be noted that differences in health care systems (private/
public, financing, etc.) might have a significant impact on 
costs; for instance, global budget, fee-for-service or DRG 
financing mechanisms, the presence of co-payments, minor Ta
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Fig. 2  Total costs (euro 2017) and GDP per capita (2017): compari-
son of single-country and multi-country studies. a Single-country 
studies: each line represents one disease, and each dot represents one 
study and one country. b Multi-country studies: each line represents 
one study and one disease, and each dot represents one country
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or major share of private services, and many more aspects 
might influence the actual costs, access to health care, and, 
finally, the COI figure [42].
According to the literature, one might expect a higher 
COI in a country with a higher GDP [43–45]. In many 
diseases (multiple sclerosis, bladder cancer, Parkinson’s 
disease, rheumatoid arthritis, Prader–Willi syndrome, hae-
mophilia, diabetes, and hypoglycaemia), there was a clear 
positive association between total costs and GDP per capita. 
As opposed to this, cost estimates, sometimes, inversely 
correlated with the per capita GDP. For instance, GDP per 
capita in Bulgaria is almost half of that in Hungary; nev-
ertheless, costs of mucopolysaccharidosis were threefold 
higher in Bulgaria. Thus, in some cases, adjusting costs for 
the GDP further increased the inter-country differences. On 
the other hand, the 3.5-fold higher GDP per capita in Austria 
decreased the cross-country differences (from 4- to 1.3-fold) 
in costs of multiple sclerosis. In spite of the considerable 
heterogeneity observed in the studies included in this review, 
some trends could be identified. The magnitude of costs 
increased with the level of per capita GDP. In other words, 
cross-country differences decreased or even vanished when 
the costs were adjusted. In contrast, higher costs with lower 
GDP per capita could be observed only in some rare diseases 
(cystic fibrosis, epidermolysis bullosa, and mucopolysaccha-
ridosis) and rotavirus gastroenteritis. Moreover, methodo-
logical differences did not seem to affect this relationship. 
Comparing multi-country studies in a disease applied the 
same methodology for more than one country and single-
country studies analysed costs in the same disease, the rela-
tionship between cost-of-illness and GDP per capita showed 
similar pattern in these two groups of studies (see Fig. 2).
Quality, publication standards, and the assessment 
of transferability
Cost-of-illness studies varied considerably both in methods 
and in cost estimates, and serve many purposes. Methodo-
logical deficiencies, such as the lack of reporting either on 
the three distinct phases of costing (identifying the relevant 
cost items, measuring the use of the identified resources, and 
placing a value on these cost items) [46], or other important 
characteristics such as the perspective of the study, related to 
the production function (direct and indirect costs) were the 
leading causes of shortcomings in comparability. However, 
no specific costing guidelines for health care interventions 
are available in these countries, and except in Austria, there 
is no national cost database available, providing some kind 
of unit cost data in a collected form [13, 47, 48]. Another 
important difficulty in costing relates to the different Managed 
Entry Agreements (MEA), such as price volume agreements, 
discounts, outcome guarantees, and many more, in the reim-
bursement of the health technologies in the different countries 
[49, 50]. Due to the MEAs, for instance, the real purchasing 
price of the medicinal products is not publicly available.
Several papers were published about transferability in 
the past 2 decades [51–56]. At the moment, health econom-
ics and health technology assessment guidelines in CEE 
countries either include very limited advice or provide no 
guidance on the transferability or adaptation of clinical and 
economic data from other jurisdictions. Thus, establishing 
better guidelines for COI studies on transferability would be 
valuable for robust decision-making in the CEE countries 
[56]. As Gao et al. stated, confirming the transferability of 
COI estimates across jurisdictions would contribute signifi-
cantly to resolving the issue of transferability of cost-effec-
tiveness results [45]. Transferability is a very important issue 
around the world and especially in Central or Eastern Europe 
with limited resources to provide COI studies [53–55]. Data 
transferability and transferability of the results are not dis-
cussed in these COI studies. Both should be improved using 
Drummond’s check list for evaluating economic evaluations 
[57]. Transferability might be an important alternative to 
conduct local COIs. However, due to the methodological, 
data, and publication heterogeneity, the usefulness of the 
COI results in other jurisdictions is limited.
Limitations
There are a few limitations to note. A systematic approach 
was taken to identify studies that have considered the costs 
of diseases; however, the possibility that relevant studies 
were not identified and included in this systematic literature 
review remains. Some COI results might have been missed 
due to excluding grey literature (i.e., conference abstracts 
and project reports) from our search. Other limitationis that 
the local search in non-indexed journals was conducted only 
in three of the nine countries. On the other hand, no language 
restriction was applied in the systematic search. Adopting 
a Medical Subject Heading (MeSH)-based search strat-
egy may have led to missing some studies using keywords 
improperly. At the same time, the PubMed search engine 
uses a broad range of entry terms which may minimize the 
number of excluded studies. Further limitation is that no 
comprehensive checklist was applied, because, according to 
our best knowledge, there is no COI study-specific checklist 
in English. This might bias our conclusions on study quality, 
but we believe that the presented study characteristics could 
give a good overall description of the included studies.
Conclusions
Fifty-eight COI studies were identified between 1 Janu-
ary 2006 and 30 June 2017 published in Austria, Bulgaria, 
the Czech Republic, Croatia, Hungary, Poland, Romania, 
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Slovakia, and Slovenia, providing 83 country-specific COI 
results. Endocrine, nutritional, and metabolic diseases, neo-
plasms, infectious disease, and neurological disorders were 
the most frequently studied clinical areas. Transferability 
might be an important alternative to conduct local COIs. 
However, due to the methodological, data, and publication 
heterogeneity of these 58 COI studies, the transferability 
is limited across the nine Central and Eastern European 
Countries.
Acknowledgements Open access funding provided by Corvinus Uni-
versity of Budapest (BCE). This research was supported by the Higher 
Education Institutional Excellence Program of the Ministry of Human 
Capacities in the framework of the ‘Financial and Public Services’ 
research project (20764-3/2018/FEKUTSTRAT) at Corvinus Univer-
sity of Budapest.
Compliance with ethical standards 
Conflict of interest The authors declare no conflict of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Drummond, M., Sculpher, M., Torrance, G.: Methods for the 
economic evaluation of health care programmes, 3rd edn. Oxford 
University PressOxford University Press, Oxford (2005)
 2. Tarricone, R.: Cost-of-illness analysis. What room in health 
economics? Health Policy 77(1), 51–63 (2006). https ://doi.
org/10.1016/j.healt hpol.2005.07.016
 3. Gulacsi, L., Rotar, A.M., Niewada, M., Loblova, O., Rencz, F., 
Petrova, G., Boncz, I., Klazinga, N.S.: Health technology assess-
ment in Poland, the Czech Republic, Hungary, Romania and Bul-
garia. Eur. J. Health Econ. 15(Suppl 1), S13–S25 (2014). https ://
doi.org/10.1007/s1019 8-014-0590-8
 4. Boncz, I., Sebestyen, A.: Financial deficits in the health services 
of the UK and Hungary. Lancet 368(9539), 917–918 (2006). https 
://doi.org/10.1016/S0140 -6736(06)69369 -0
 5. Feig, C., Cheung, K.L., Hiligsmann, M., Evers, S., Simon, J., 
Mayer, S.: Best-worst scaling to assess the most important barri-
ers and facilitators for the use of health technology assessment in 
Austria. Expert Rev. Pharmacoecon. Outcomes Res. (2017). https 
://doi.org/10.1080/14737 167.2017.13754 07
 6. Larg, A., Moss, J.R.: Cost-of-illness studies: a guide to critical 
evaluation. PharmacoEconomics 29(8), 653–671 (2011). https ://
doi.org/10.2165/11588 380-00000 0000-00000 
 7. Jacobs, P., Ohinmaa, A., Brady, B.: Providing systematic guidance 
in pharmacoeconomic guidelines for analysing costs. Pharmaco-
economics 23(2), 143–153 (2005)
 8. Brouwer, W., Rutten, F., Koopmanschap, M.: Costing in economic 
evaluations. In: Drummond, M., McGuire, A. (eds.) Economic 
evaluations in health care: merging theory with practice. Oxford 
University Press, New York (2001)
 9. Angelis, A., Tordrup, D., Kanavos, P.: Socio-economic burden 
of rare diseases: a systematic review of cost of illness evidence. 
Health Policy 119(7), 964–979 (2015). https ://doi.org/10.1016/j.
healt hpol.2014.12.016
 10. Onukwugha, E., McRae, J., Kravetz, A., Varga, S., Khairnar, R., 
Mullins, C.D.: Cost-of-illness studies: an updated review of cur-
rent methods. PharmacoEconomics 34(1), 43–58 (2016). https ://
doi.org/10.1007/s4027 3-015-0325-4
 11. Clabaugh, G., Ward, M.M.: Cost-of-illness studies in the United 
States: a systematic review of methodologies used for direct 
cost. Value Health 11(1), 13–21 (2008). https ://doi.org/10.111
1/j.1524-4733.2007.002
 12. Oliva-Moreno, J., Trapero-Bertran, M., Pena-Longobardo, L.M., 
Del Pozo-Rubio, R.: The valuation of informal care in cost-of-
illness studies: a systematic review. PharmacoEconomics 35(3), 
331–345 (2017). https ://doi.org/10.1007/s4027 3-016-0468-y
 13. Mayer, S., Kiss, N., Laszewska, A., Simon, J.: Costing evidence 
for health care decision-making in Austria: a systematic review. 
PLoS One 12(8), e0183116 (2017). https ://doi.org/10.1371/journ 
al.pone.01831 16
 14. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G.: Preferred 
reporting items for systematic reviews and meta-analyses: the 
PRISMA statement. PLoS Med. 6(7), e1000097 (2009). https ://
doi.org/10.1371/journ al.pmed.10000 97
 15. Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, 
D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J., 
Loder, E., Force, C.T.: Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) statement. Value Health 16(2), 
e1–e5 (2013). https ://doi.org/10.1016/j.jval.2013.02.010
 16. Eurostat: ECU/EUR exchange rates versus national currencies. 
http://ec.europ a.eu/euros tat/estat -navtr ee-portl et-prod/NodeI nfoSe 
rvice s?lang=en&code=tec00 033 Accessed 19 Sep 2017
 17. International Statistical Classification of Diseases and Related 
Health Problems, 10th Revision (ICD-10 Version:2016) (2016). 
http://apps.who.int/class ifica tions /icd10 /brows e/2016/en 
Accessed 21 Jul 2017
 18. Georgieva, V.: Pharmacoeconomic evaluation of surgical and 
endovascular therapy of brain aneurism. PhD thesis, Medical 
University of Sofia (2015)
 19. Glogovska, P., Ivanov, Y., Hristova, P., Pavlov, P., Popova, T.E.B.: 
Pharmacoeconomic evaluation of the ambulatory and hospital cost 
of therapy of patients with community acquired respiratory tract 
infections. Thorasis Med. 2(3), 52–56 (2010)
 20. Ivanova, Z., Veleva, N., Glogovska, P., Pavlov, P., Popova, T., 
Ivanov, Y.: Hospital therapy cost of patients with asthma. MED-
INFO 14(12), 28–31 (2014)
 21. Kyuchukov, N., Yanev, N., Krachunov, I., Ivanova, Z., Pavlov, P., 
Popova, T., Glogovska, P., Hristova, P., Ivanov, Y.: Evaluation of 
COPD cost for patients on home oxygen therapy. Thorasic Med. 
7(4), 50–56 (2015)
 22. Todorova, K.: Pharmacoeconomic analysis of the gestational dia-
betes therapy during pregnancy. PhD thesis, Medical University 
of Sofia (2007)
 23. Blahova Dusankova, J., Kalincik, T., Dolezal, T., Kobelt, G., 
Havrdova, E.: Cost of multiple sclerosis in the Czech Republic: 
the COMS study. Mult. Scler. 18(5), 662–668 (2012). https ://doi.
org/10.1177/13524 58511 42442 2
 24. Kobelt, G., Berg, J., Lindgren, P., Plesnilla, C., Baumhackl, U., 
Berger, T., Kolleger, H., Vass, K.: Costs and quality of life of 
multiple sclerosis in Austria. Eur. J. Health Econ. 7(Suppl 2), 
S14–S23 (2006). https ://doi.org/10.1007/s1019 8-006-0382-x
 25. Szmurlo, D., Fundament, T., Ziobro, M., Kruntoradova, K., 
Dolezal, T., Glogowski, C.: Costs of multiple sclerosis—extrap-
olation of Czech data to Polish patients. Expert Rev. Pharma-
coecon. Outcomes Res. 14(3), 451–458 (2014). https ://doi.
org/10.1586/14737 167.2014.90630 5
S170 V. Brodszky et al.
1 3
 26. Pentek, M., Harangozo, J., Egerhazi, A., Kelemen, O., Gulacsi, 
L., Baji, P., Mattyassy, A., Erdelyi, R., Lehoczky, S., Orlewska, 
E., Vartokne Hever, N., Ferencz, A., Brodszky, V.: Health related 
quality of life and disease burden of patients with schizophrenia 
in Hungary. Psychiatr. Hung. 27(1), 4–17 (2012)
 27. Jakubczyk, M., Lipka, I., Paweska, J., Niewada, M., Rdzanek, 
E., Zaletel, J., Ramirez de Arellano, A., Dolezal, T., Chekorova 
Mitreva, B., Nagy, B., Petrova, G., Saric, T., Yfantopoulos, J., 
Czech, M.: Cost of severe hypoglycaemia in nine European 
countries. J. Med. Econ. 19(10), 973–982 (2016). https ://doi.
org/10.1080/13696 998.2016.11888 23
 28. Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Posada-
de-la-Paz, M., Serrano-Aguilar, P., Kanavos, P., Taruscio, D., 
Schieppati, A., Iskrov, G., Baji, P., Delgado, C., von der Schu-
lenburg, J.M., Persson, U., Chevreul, K., Fattore, G., Network, 
B.-R.R.: Social/economic costs and health-related quality of life 
in patients with Prader-Willi syndrome in Europe. Eur J Health 
Econ 17(Suppl 1), 99–108 (2016). https ://doi.org/10.1007/s1019 
8-016-0788-z
 29. Pentek, M., Gulacsi, L., Brodszky, V., Baji, P., Boncz, I., Pog-
any, G., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., 
Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, D., Isk-
rov, G., Schieppati, A., von der Schulenburg, J.M., Kanavos, P., 
Chevreul, K., Persson, U., Fattore, G., Network, B.-R.R.: Social/
economic costs and health-related quality of life of mucopolysac-
charidosis patients and their caregivers in Europe. Eur J Health 
Econ 17(Suppl 1), 89–98 (2016). https ://doi.org/10.1007/s1019 
8-016-0787-0
 30. Pentek, M., Gulacsi, L., Rozsa, C., Simo, M., Iljicsov, A., Komoly, 
S., Brodszky, V.: Health status and costs of ambulatory patients 
with multiple sclerosis in Hungary. Ideggyogy Sz 65(9–10), 316–
324 (2012)
 31. Nerat, T., Kos, M.: Burden of Type 2 Diabetes from the Healthcare 
Payer Perspective in Slovenia/Breme Sladkorne Bolezni Tipa 2 
S Stališča Plačnika Zdravstvenega Varstva V Sloveniji. Slov. J. 
Public Health (2013). https ://doi.org/10.2478/sjph-2013-0018
 32. Valov, V., Doneva, M., Borisova, A.M., Tankova, T., Czech, M., 
Manova, M., Savova, A., Peikova, L., Petrova, G.: Regional dif-
ferences in diabetic patients’ pharmacotherapy in Bulgaria. Eur 
Rev Med Pharmacol Sci 18(10), 1499–1506 (2014)
 33. von Campenhausen, S., Winter, Y., Gasser, J., Seppi, K., Reese, 
J.P., Pfeiffer, K.P., Geiger-Gritsch, S., Botzel, K., Siebert, U., Oer-
tel, W.H., Dodel, R., Poewe, W.: Cost of illness and health service 
patterns in Morbus Parkinson in Austria. Wien. Klin. Wochen-
schr. 121(17–18), 574–582 (2009). https ://doi.org/10.1007/s0050 
8-009-1223-6
 34. Winter, Y., von Campenhausen, S., Brozova, H., Skoupa, J., 
Reese, J.P., Botzel, K., Eggert, K., Oertel, W.H., Dodel, R., Ruz-
icka, E.: Costs of Parkinson’s disease in eastern Europe: a Czech 
cohort study. Parkinsonism Relat Disord 16(1), 51–56 (2010). 
https ://doi.org/10.1016/j.parkr eldis .2009.07.005
 35. Ersek, K., Kovacs, T., Wimo, A., Karpati, K., Brodszky, V., 
Pentek, M., Jonsson, L., Gustavsson, A., McDaid, D., Kenigsberg, 
P.A., Valtonen, H., Gulacsi, L.: Costs of dementia in Hungary. J 
Nutr Health Aging 14(8), 633–639 (2010)
 36. Holmerova, I., Hort, J., Rusina, R., Wimo, A., Steffl, M.: Costs of 
dementia in the Czech Republic. Eur J Health Econ (2016). https 
://doi.org/10.1007/s1019 8-016-0842-x
 37. Stambu, I., Stoicescu, I.P.: Estimation of direct medical costs of 
chronic obstructive pulmonary disease over 12 months. Pneumo-
logia 62(2), 86–92 (2013)
 38. DALYs G, Collaborators, H.: Global, regional, and national dis-
ability-adjusted life-years (DALYs) for 333 diseases and injuries 
and healthy life expectancy (HALE) for 195 countries and ter-
ritories, 1990–2016: a systematic analysis for the Global Burden 
of Disease Study 2016. Lancet 390(10100), 1260–1344 (2017). 
https ://doi.org/10.1016/s0140 -6736(17)32130 -x
 39. Rencz, F., Gulacsi, L., Drummond, M., Golicki, D., Prevolnik 
Rupel, V., Simon, J., Stolk, E.A., Brodszky, V., Baji, P., Zavada, J., 
Petrova, G., Rotar, A., Pentek, M.: EQ-5D in Central and Eastern 
Europe: 2000–2015. Qual. Life Res. 25(11), 2693–2710 (2016). 
https ://doi.org/10.1007/s1113 6-016-1375-6
 40. Brodszky, V., Varga, P., Gimesi-Orszagh, J., Fadgyas-Freyler, P., 
Boncz, I., Nyirady, P., Riesz, P., Baji, P., Pentek, M., Rencz, F., 
Gulacsi, L.: Long-term costs and survival of prostate cancer: a 
population-based study. Int. Urol. Nephrol. 49(10), 1707–1714 
(2017). https ://doi.org/10.1007/s1125 5-017-1669-9
 41. Inotai, A., Abonyi-Tóth, Z., Rokszin, G., Vokó, Z.: Prognosis, 
cost, and occurrence of colorectal, lung, breast, and prostate can-
cer in hungary. Value Health Reg Issues 7, 1–8 (2015). https ://doi.
org/10.1016/j.vhri.2015.03.020
 42. European Observatory on Health Systems and Policies: Health 
system reviews (HiT series) http://www.euro.who.int/en/about -us/
partn ers/obser vator y/publi catio ns/healt h-syste m-revie ws-hits/full-
list-of-count ry-hits. Accessed 03 Nov 2018
 43. Seuring, T., Archangelidi, O., Suhrcke, M.: The economic costs 
of type 2 diabetes: a global systematic review. Pharmacoeco-
nomics 33(8), 811–831 (2015). https ://doi.org/10.1007/s4027 
3-015-0268-9
 44. Zhao, F.L., Xie, F., Hu, H., Li, S.C.: Transferability of indirect cost 
of chronic disease: a systematic review and meta-analysis. Phar-
macoeconomics 31(6), 501–508 (2013). https ://doi.org/10.1007/
s4027 3-013-0053-6
 45. Gao, L., Hu, H., Zhao, F.L., Li, S.C.: Can the direct medical cost 
of chronic disease be transferred across different countries? Using 
cost-of-illness studies on type 2 diabetes, epilepsy and schizophre-
nia as examples. PLoS One 11(1), e0147169 (2016). https ://doi.
org/10.1371/journ al.pone.01471 69
 46. Brouwer, W., Rutten, F., Koopmanschap, M.: Costing in economic 
evaluations, chapter 4 p. 68-94. In: Drummond, M., McGuire, A. 
(eds.) Economic Evaluation in Health Care. OHE Oxford Univer-
sity Press, Oxford (2001)
 47. Mayer, S., Kiss, N., Laszewska, A., Simon, J.: Health economic 
costing methods and reporting in Austria. Value Health 19(7), 
A363 (2016)
 48. DHE Unit Cost Online Database: Cost Collection from Existing 
Studies. Version 2.2/2017. Vienna: Department of Health Eco-
nomics (DHE), Center for Public Health, Medical University of 
Vienna (2017)
 49. Rotar, A.M., Preda, A., Löblová, O., Benkovic, Zawodnik, V.S., 
Gulacsi, L., Niewada, M., Boncz, I., Petrova, G., Dimitrova, M., 
Klazinga, N.: Rationalizing the introduction and use of pharma-
ceutical products: the role of managed entry agreements in Central 
and Eastern European countries, 2018, Health Policy accepted for 
publication (2018)
 50. Ferrario A, Kanavos P. Managed entry agreements for pharma-
ceuticals: the European experience. 2013. EMiNet, Brussels, 
Belgium. http://eprin ts.lse.ac.uk/50513 /1/__Libfi le_repos itory 
_Conte nt_Ferra rio%2C%20A_Ferra rio_Manag ed_%20ent ry_%20
agr eemen ts_2013_Ferra rio_Manag ed_%20ent ry_%20agr eemen 
ts_2013.pdf. Accessed 02 Nov 2018
 51. Nixon, J., Rice, S., Drummond, M., Boulenger, S., Ulmann, P., de 
Pouvourville, G.: Guidelines for completing the EURONHEED 
transferability information checklists. Eur. J. Health Econ. 10(2), 
157–165 (2009). https ://doi.org/10.1007/s1019 8-008-0115-4
 52. de Pouvourville, G., Ulmann, P., Nixon, J., Boulenger, S., Glan-
ville, J., Drummond, M.: The diffusion of health economics 
knowledge in Europe: the EURONHEED (European Network of 
Health Economics Evaluation Database) project. Pharmacoeco-
nomics 23(2), 113–120 (2005)
S171Cost-of-illness studies in nine Central and Eastern European countries 
1 3
 53. Drummond, M., Brown, R., Fendrick, A.M., Fullerton, P., Neu-
mann, P., Taylor, R., Barbieri, M., Force, I.T.: Use of pharmaco-
economics information–report of the ISPOR task force on use of 
pharmacoeconomic/health economic information in health-care 
decision making. Value Health 6(4), 407–416 (2003)
 54. Barbieri, M., Drummond, M., Rutten, F., Cook, J., Glick, 
H.A., Lis, J., Reed, S.D., Sculpher, M., Severens, J.L., Force, 
I.G.R.P.E.D.T.T.: What do international pharmacoeconomic 
guidelines say about economic data transferability? Value 
Health 13(8), 1028–1037 (2010). https ://doi.org/10.111
1/j.1524-4733.2010.00771 .x
 55. Mandrik, O., Knies, S., Kalo, Z., Severens, J.L.: Reviewing 
transferability in economic evaluations originating from East-
ern Europe. Int. J. Technol. Assess. Health Care 31(6), 434–441 
(2015). https ://doi.org/10.1017/S0266 46231 50006 77
 56. Gulacsi, L., Rencz, F., Pentek, M., Brodszky, V., Lopert, R., 
Hever, N.V., Baji, P.: Transferability of results of cost utility 
analyses for biologicals in inflammatory conditions for Central 
and Eastern European countries. Eur. J. Health Econ. 15(Suppl 
1), S27–S34 (2014). https ://doi.org/10.1007/s1019 8-014-0591-7
 57. Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J., 
Stoddart, G.L.: Methods for the Economic Evaluation of Health 
care Programmes, 4th edn. Oxford University Press, Oxford 
(2015)
 58. Grabmeier-Pfistershammer, K., Rieger, A., Schrock, T., Schlag, 
M.: Economic burden of late presentation in HIV disease in Aus-
tria: a comparison of the initial costs imposed by advanced HIV 
disease vs. non-late presentation. Wien Klin Wochenschr 125(13-
14), 402–407 (2013). https ://doi.org/10.1007/s0050 8-013-0392-5
 59. Leal, J., Luengo-Fernandez, R., Sullivan, R., Witjes, J.A.: Eco-
nomic burden of bladder cancer across the European union. Eur. 
Urol. 69(3), 438–447 (2016). https ://doi.org/10.1016/j.eurur 
o.2015.10.024
 60. Prast, J., Oppelt, P., Shamiyeh, A., Shebl, O., Brandes, I., Haas, 
D.: Costs of endometriosis in Austria: a survey of direct and indi-
rect costs. Arch. Gynecol. Obstet. 288(3), 569–576 (2013). https 
://doi.org/10.1007/s0040 4-013-2793-0
 61. Willich, S.N., Nocon, M., Kulig, M., Jaspersen, D., Labenz, J., 
Meyer-Sabellek, W., Stolte, M., Lind, T., Malfertheiner, P.: Cost-
of-disease analysis in patients with gastro-oesophageal reflux 
disease and Barrett’s mucosa. Aliment. Pharmacol. Ther. 23(3), 
371–376 (2006). https ://doi.org/10.1111/j.1365-2036.2006.02763 
.x
 62. Dimai, H.P., Redlich, K., Schneider, H., Siebert, U., Viernstein, 
H., Mahlich, J.: Direct and indirect costs of fractures due to osteo-
porosis in Austria. Gesundheitswesen 74(10), e90–e98 (2012). 
https ://doi.org/10.1055/s-0031-13012 74
 63. Wagner, E.: Direct costs of osteoarthritis. Wien. Med. Wochen-
schr. 161(1–2), 44–52 (2011). https ://doi.org/10.1007/s1035 
4-010-0858-2
 64. Wagner, E.: Costs of non-specific low back pain in Austria. 
Wien. Med. Wochenschr. 162(5–6), 92–98 (2012). https ://doi.
org/10.1007/s1035 4-011-0050-3
 65. Angelis, A., Kanavos, P., Lopez-Bastida, J., Linertova, R., Oliva-
Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, M., Taruscio, 
D., Schieppati, A., Iskrov, G., Brodszky, V., von der Schulen-
burg, J.M., Chevreul, K., Persson, U., Fattore, G., Network, B.-
R.R.: Social/economic costs and health-related quality of life 
in patients with epidermolysis bullosa in Europe. Eur. J. Health 
Econ. 17(Suppl 1), 31–42 (2016). https ://doi.org/10.1007/s1019 
8-016-0783-4
 66. Cavazza, M., Kodra, Y., Armeni, P., De Santis, M., Lopez-Bastida, 
J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-
de-la-Paz, M., Taruscio, D., Schieppati, A., Iskrov, G., Gulacsi, 
L., von der Schulenburg, J.M., Kanavos, P., Chevreul, K., Pers-
son, U., Fattore, G., Network, B.-R.R.: Social/economic costs 
and quality of life in patients with haemophilia in Europe. Eur. J. 
Health Econ. 17(Suppl 1), 53–65 (2016). https ://doi.org/10.1007/
s1019 8-016-0785-2
 67. Cavazza, M., Kodra, Y., Armeni, P., De Santis, M., Lopez-Bastida, 
J., Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-
de-la-Paz, M., Taruscio, D., Schieppati, A., Iskrov, G., Pentek, 
M., von der Schulenburg, J.M., Kanavos, P., Chevreul, K., Pers-
son, U., Fattore, G., Network, B.-R.R.: Social/economic costs and 
health-related quality of life in patients with Duchenne muscular 
dystrophy in Europe. Eur. J. Health Econ. 17(Suppl 1), 19–29 
(2016). https ://doi.org/10.1007/s1019 8-016-0782-5
 68. Chevreul, K., Michel, M., Brigham, K.B., Lopez-Bastida, J., 
Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-
la-Paz, M., Taruscio, D., Schieppati, A., Iskrov, G., Pentek, M., 
von der Schulenburg, J.M., Kanavos, P., Persson, U., Fattore, G., 
Network, B.-R.R.: Social/economic costs and health-related qual-
ity of life in patients with cystic fibrosis in Europe. Eur. J. Health 
Econ. 17(Suppl 1), 7–18 (2016). https ://doi.org/10.1007/s1019 
8-016-0781-6
 69. Iskrov, G., Astigarraga, I., Stefanov, R., Lopez-Bastida, J., Liner-
tova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-la-Paz, 
M., Schieppati, A., Taruscio, D., Pentek, M., von der Schulen-
burg, J.M., Kanavos, P., Chevreul, K., Persson, U., Fattore, G., 
Network, B.-R.R.: Social/economic costs and health-related qual-
ity of life in patients with histiocytosis in Europe. Eur. J. Health 
Econ. 17(Suppl 1), 67–78 (2016). https ://doi.org/10.1007/s1019 
8-016-0790-5
 70. Iskrov, G.G., Stefanov, R.S., Lopez-Bastida, J., Linertova, R., 
Oliva-Moreno, J., Serrano-Aguilar, P., Network, B.-R.R.: Eco-
nomic burden and health-related quality of life of patients with 
cystic fibrosis in Bulgaria. Folia Med (Plovdiv) 57(1), 56–64 
(2015). https ://doi.org/10.1515/folme d-2015-0020
 71. Bencina, G., Buljan, M., Situm, M., Stevanovic, R., Benkovic, V.: 
Health and economic burden of skin melanoma in croatia—cost-
of-illness study. Acta Dermatovenerol. Croat. 25(1), 1–7 (2017)
 72. Klimeš, J., Vocelka, M., Šedová, L., Doležal, T., Mlčoch, T., 
Petříková, A., Vlček, J.: Medical and productivity costs of rheu-
matoid arthritis in The Czech Republic: cost-of-illness study 
based on disease severity. Value in Health Regional Issues 4, 
75–81 (2014). https ://doi.org/10.1016/j.vhri.2014.07.004
 73. Maresova, P., Zahalkova, V.: The economic burden of the care and 
treatment for people with Alzheimer’s disease: the outlook for the 
Czech Republic. Neurol Sci 37(12), 1917–1922 (2016). https ://
doi.org/10.1007/s1007 2-016-2679-6
 74. Mlcoch, T., Klimes, J., Fila, L., Vavrova, V., Skalicka, V., Turn-
ovec, M., Krulisova, V., Jircikova, J., Zemkova, D., Dedeckova, 
K.V., Bilkova, A., Fruhaufova, V., Homola, L., Friedmannova, 
Z., Drnek, R., Drevinek, P., Dolezal, T., Macek Jr., M.: Cost-
of-illness analysis and regression modeling in cystic fibrosis: a 
retrospective prevalence-based study. Eur. J. Health Econ. 18(1), 
73–82 (2017). https ://doi.org/10.1007/s1019 8-015-0759-9
 75. Tichopad, A., Mullerova, J., Jackowska, T., Nemes, E., Pazdiora, 
P., Sloesen, B., Stefkovicova, M.: Cost burden of severe commu-
nity-acquired rotavirus gastroenteritis requiring hospitalization 
in the Czech Republic, Slovakia, Poland, and Hungary: a retro-
spective patient chart review. Value Health Reg Issues 10, 53–60 
(2016). https ://doi.org/10.1016/j.vhri.2016.07.005
 76. Tichopad, A., Roberts, C., Gembula, I., Hajek, P., Skoczynska, A., 
Hryniewicz, W., Jahnz-Rozyk, K., Prymula, R., Solovic, I., Kolek, 
V.: Clinical and economic burden of community-acquired pneu-
monia among adults in the Czech Republic, Hungary, Poland and 
Slovakia. PLoS One 8(8), e71375 (2013). https ://doi.org/10.1371/
journ al.pone.00713 75
 77. Balogh, O., Brodszky, V., Gulacsi, L., Heredi, E., Herszenyi, K., 
Jokai, H., Karpati, S., Baji, P., Remenyik, E., Szegedi, A., Hollo, 
P.: Cost-of-illness in patients with moderate to severe psoriasis: 
S172 V. Brodszky et al.
1 3
a cross-sectional survey in Hungarian dermatological centres. 
Eur. J. Health Econ. 15(Suppl 1), S101–S109 (2014). https ://doi.
org/10.1007/s1019 8-014-0599-z
 78. Brodszky, V., Balint, P., Geher, P., Hodinka, L., Horvath, G., Koo, 
E., Pentek, M., Polgar, A., Sesztak, M., Szanto, S., Ujfalussy, 
I., Gulacsi, L.: Disease burden of psoriatic arthritis compared to 
rheumatoid arthritis, Hungarian experiment. Rheumatol Int 30(2), 
199–205 (2009). https ://doi.org/10.1007/s0029 6-009-0936-1
 79. Chevreul, K., Gandre, C., Brigham, K.B., Lopez-Bastida, J., 
Linertova, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-de-
la-Paz, M., Taruscio, D., Schieppati, A., Iskrov, G., Gulacsi, L., 
von der Schulenburg, J.M., Kanavos, P., Persson, U., Fattore, G., 
Network, B.-R.R.: Social/economic costs and health-related qual-
ity of life in patients with fragile X syndrome in Europe. Eur. J. 
Health Econ. 17(Suppl 1), 43–52 (2016). https ://doi.org/10.1007/
s1019 8-016-0784-3
 80. Gulacsi, L., Majer, I., Boncz, I., Brodszky, V., Merkely, B., Mau-
rovich, H.P., Karpati, K.: Health care costs of acute myocardial 
infarction in Hungary, 2003–2005. Orv. Hetil. 148(27), 1259–
1266 (2007). https ://doi.org/10.1556/OH.2007.28109 
 81. Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., Serrano-Agu-
ilar, P., Posada-de-la-Paz, M., Kanavos, P., Taruscio, D., Schiep-
pati, A., Iskrov, G., Pentek, M., Delgado, C., von der Schulenburg, 
J.M., Persson, U., Chevreul, K., Fattore, G., Network, B.-R.R.: 
Social/economic costs and health-related quality of life in patients 
with scleroderma in Europe. Eur. J. Health Econ. 17(Suppl 1), 
109–117 (2016). https ://doi.org/10.1007/s1019 8-016-0789-y
 82. Minier, T., Pentek, M., Brodszky, V., Ecseki, A., Karpati, K., 
Polgar, A., Czirjak, L., Gulacsi, L.: Cost-of-illness of patients 
with systemic sclerosis in a tertiary care centre. Rheumatology 
(Oxford) 49(10), 1920–1928 (2010). https ://doi.org/10.1093/
rheum atolo gy/keq16 5
 83. Pentek, M., Bereczki, D., Gulacsi, L., Mikudina, B., Aranyi, Z., 
Juhos, V., Baji, P., Brodszky, V.: Survey of adults living with 
epilepsy in Hungary: health-related quality of life and costs. Ideg-
gyogy Sz 66(7–8), 251–261 (2013)
 84. Rencz, F., Kovacs, A., Brodszky, V., Gulacsi, L., Nemeth, Z., 
Nagy, G.J., Nagy, J., Buzogany, I., Boszormenyi-Nagy, G., 
Majoros, A., Nyirady, P.: Cost of illness of medically treated 
benign prostatic hyperplasia in Hungary. Int. Urol. Nephrol. 47(8), 
1241–1249 (2015). https ://doi.org/10.1007/s1125 5-015-1028-7
 85. Tamas, G., Gulacsi, L., Bereczki, D., Baji, P., Takats, A., Brod-
szky, V., Pentek, M.: Quality of life and costs in Parkinson’s dis-
ease: a cross sectional study in Hungary. PLoS One 9(9), e107704 
(2014). https ://doi.org/10.1371/journ al.pone.01077 04
 86. Pentek, M., Kobelt, G., Czirjak, L., Szekanecz, Z., Poor, G., 
Rojkovich, B., Polgar, A., Genti, G., Kiss, C.G., Brodszky, V., 
Majer, I., Gulacsi, L.: Costs of rheumatoid arthritis in Hungary. 
J. Rheumatol. 34(6), 1437 (2007)
 87. Czech, M., Rosinska, M., Rogalska, J., Staszewska, E., Stefanoff, 
P.: Costs of medically attended acute gastrointestinal infections: 
the polish prospective healthcare utilization survey. Value Health 
Reg Issues 2(2), 210–217 (2013). https ://doi.org/10.1016/j.
vhri.2013.06.011
 88. Dubas-Jakobczyk, K., Kocot, E., Seweryn, M., Koperny, M.: Pro-
duction lost due to cervical cancer in Poland in 2012. Med. Pr. 
67(3), 289–299 (2016). https ://doi.org/10.13075 /mp.5893.00378 
 89. Jaworski, R., Jankowska, E.A., Ponikowski, P., Banasiak, W.: 
Costs of management of patients with coronary artery disease in 
Poland: the multicenter RECENT study. Pol. Arch. Med. Wewn. 
122(12), 599–607 (2012)
 90. Kawalec, P.P., Malinowski, K.P.: The indirect costs of systemic 
autoimmune diseases, systemic lupus erythematosus, systemic 
sclerosis and sarcoidosis: a summary of 2012 real-life data from 
the Social Insurance Institution in Poland. Expert Rev Phar-
macoecon Outcomes Res 15(4), 667–673 (2015). https ://doi.
org/10.1586/14737 167.2015.10657 33
 91. Lesniowska, J., Schubert, A., Wojna, M., Skrzekowska-Baran, 
I., Fedyna, M.: Costs of diabetes and its complications in 
Poland. Eur. J. Health Econ. 15(6), 653–660 (2014). https ://doi.
org/10.1007/s1019 8-013-0513-0
 92. Czech, M., Opolski, G., Zdrojewski, T., Dubiel, J.S., Wizner, B., 
Bolisega, D., Fedyk-Lukasik, M., Grodzicki, T.: The costs of heart 
failure in Poland from the public payer’s perspective. Polish pro-
gramme assessing diagnostic procedures, treatment and costs in 
patients with heart failure in randomly selected outpatient clinics 
and hospitals at different levels of care: POLKARD. Kardiol Pol 
71(3), 224–232 (2013). https ://doi.org/10.5603/kp.2013.0032
 93. Stoicescu, I.P., Mihaescu, T., Azoicai, D., Arama, V., Balcu, I.: 
Preliminary assessment of Streptococcus pneumoniae, pneumo-
nia, economical and clinical burden in Romania. Pneumologia 
56(3), 118–123 (2007)
 94. Dzajkovska, B., Wertheimer, A.I., Mrhar, A.: The burden-of-
illness study on osteoporosis in the Slovenian female population. 
Pharm. World Sci. 29(4), 404–411 (2007). https ://doi.org/10.1007/
s1109 6-007-9091-5
 95. Kopcsóné-Németh, I., Kertész, A., Strbák, B., Gulácsi, L.: A 
Clostridium difficile fertőzések költsége magyarországi kórházak-
ban. Egészségügyi Gazdasági Szemle 13(2), 9–15 (2013)
 96. Ernstsson, O., Gyllensten, H., Alexanderson, K., Tinghog, P., 
Friberg, E., Norlund, A.: Cost of illness of multiple sclerosis—a 
systematic review. PLoS One 11(7), e0159129 (2016). https ://doi.
org/10.1371/journ al.pone.01591 29
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
